TriSalus Life Sciences, Inc.

NASDAQ:TLSI

Medical - Devices

Healthcare
$2.18 +0.49%

+$0.02 today

Market cap
$134.20M
Beta
0.49
P/E (TTM)
-7.4
EPS (TTM)
-$0.53
52W Low $2.20High $7.95

Volume 0.36M

Average 0.38M

Returns on capital

TriSalus Life Sciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

115.8%

avg 136.1%

ROIC

-112.3%

avg -101.9%

ROA

-111.0%

avg -195.6%

Analysis

ROE is currently the strongest return metric at 115.8% versus its period average of 136.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Mary T. Szela

Chief Executive Officer, President & DirectorUSD 769.84K631.07M2.84%

Jennifer L. Stevens

Chief Regulatory, Quality and Therapeutics OfficerUSD 630K64——

David Patience

Chief Financial OfficerUSD 585.33K40261.11K0.69%

Richard Marshak

Chief Commercial OfficerUSD 564.47K67127.99K0.34%

Richard Marshall

Chief Medical Officer————

Andrea Marasso

Vice President of Marketing————

Bryan F. Cox

Chief of Research—64162.81K0.43%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

12

$3.61M

Sells

18

$139,921.67

Net Transaction Value

+$3.47M

Net buying

Most Active

Marshak Richard

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 5, 26

Stevens Jennifer

Direct

Sell$1.4K
Oct 5, 26

Marshak Richard

Direct

Sell$1.4K
Oct 5, 26

Cox Bryan F.

Direct

Sell$1.3K
May 15, 26

Stansky Michael P

Direct

Buy$1M
May 15, 26

Gordon Gary B.

Direct

Buy$24.6K
May 15, 26

Patience David

Direct

Buy$17.3K
May 15, 26

Szela Mary T

Direct

Buy$102.8K
May 15, 26

Marshak Richard

Direct

Sell$1.4K
May 15, 26

Wahlstrom Mats

Direct

Buy$151.8K
May 15, 26

Stansky Michael P

Indirect

Buy$500K

1–10 of 30

Summary

Insiders reported 12 buys worth $3.61M and 18 sells worth $139,921.67 over the last 12 months. That adds up to net buying of $3.47M. Marshak Richard was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+53.9%
+27.0% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +53.9% over three years. Forward estimates point to Revenue at +27.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does TriSalus Life Sciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about TLSI's management, answered from reported figures.

Who manages TLSI?

TriSalus Life Sciences, Inc. (TLSI) lists 7 active executives. The top listed executive is Richard Marshak, Chief Commercial Officer.

Are TLSI insiders buying or selling?

Recent insider activity shows net buying of $32.98M.